Healthcare Industry News: brachytherapy
News Release - April 28, 2016
Varian Gives European Clinicians First Glimpse of Next Big Advance in Radiotherapy at ESTRO 35TURIN, Italy, April 28, 2016 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems will demonstrate its full range of radiotherapy delivery systems at the 35th ESTRO (European Society for Radiotherapy and Oncology) meeting, taking place here in Turin from April 29th-May 3rd. The Varian booth features the company's technology and products for radiotherapy, radiosurgery, brachytherapy, and proton therapy, and will offer the European clinical community its first glimpse of High Definition Radiotherapy (HDRT).
Visitors to the Varian booth (No. 5500) can learn about the company's four pi (4p) non-coplanar treatment technology*, which exploits specific capabilities of the TrueBeam® platform and is designed to deliver more compact radiation doses that may fully saturate a targeted tumor and "fall off" sharply outside the target zone, potentially minimizing dose to specific organs requiring more protection.
"We believe this technology could enable High Definition Radiotherapy — the next big advance in radiation oncology, rivaling the development of IMRT in the 1990s, IGRT and volumetric modulated arc therapy (VMAT) in the 2000s, and linac-based radiosurgery in more recent years," says Kolleen Kennedy, president of Varian's Oncology Systems group. "This has the potential to make a big difference in the treatment of cancer patients."
Also on display on the Varian (VAR) booth is the company's TrueBeam® platform for radiotherapy and radiosurgery, along with the RapidArc® image-guided intensity-modulated radiotherapy system, the PerfectPitch™ six-degrees-of-freedom couch, and the Calypso® 'GPS for the Body' system, all of which are aimed at helping clinicians to deliver treatments with both precision and speed. Varian will also exhibit its powerful family of oncology software products, including RapidPlan™ software for improving the quality and speed of treatment planning.
Additionally, the Varian booth is spotlighting the company's ProBeam® system, a fully-integrated image-guided IMPT (intensity-modulated proton therapy) solution, which incorporates pencil-beam scanning technology to optimize the dose applied to every point within the area being treated. Varian was recently selected to equip national proton therapy centers in Holland, Denmark and the UK with the ProBeam system.
Varian is hosting an ESTRO symposium entitled 'Moving Radiotherapy towards the Horizon' at 1.10pm on Sunday May 1st. This event will be chaired by Dr. Patrick Kupelian, Varian's vice president of clinical affairs, and will feature presentations from Dr. Clive Peedell from South Tees Hospital in Middlesbrough, UK, and Dr. Max Dahele of VU University Medical Center in Amsterdam. These presentations will focus on technological advances and challenges in accessing new technology.
*Work in Progress
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging. The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation. The company provides comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, cables and connectors as well as image processing software and workstations for use in medical and industrial settings, as well as for security and non-destructive testing. Varian Medical Systems employs approximately 7,400 people who are located at manufacturing sites in North America, Europe, and China and sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.
Forward Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry and market outlook, including customer demand and acceptance of products or technology; ongoing orders and installations, including multi-stage proton orders; growth drivers; the ability of the company's technology and products to treat cancer and other conditions or improve treatments or outcomes; and any statements using the terms "believe," "will," "potential," "can," "could," "may," "future," "next" or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the ability to effectively integrate new products into the company's; demand for the company's products; the company's ability to develop, commercialize, and deploy new products; the impact of competitive products and pricing; the effect of global economic conditions; the company's ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time the company's filings with the Securities and Exchange Commission. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsLong-Term Results from SABR-COMET Further Demonstrate Effectiveness of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Metastatic Cancers
RaySearch Enters Into Interoperability Agreement With Varian
Varian Launches New Noona(R) Capabilities to Meet Growing Demand for Remote Cancer Patient Monitoring in Response to COVID-19's Impact on Healthcare